StreetInsider.com News Articles

Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Thu, 03 Sep 2026 06:44:52 -0400

Canaccord analyst Sumant Kulkami reiterated a Buy rating and $36.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst commented: "Our thesis on ACAD is based mainly on our view that the stock is undervalued, largely on the basis of the company's approved products, Nuplazid (pimavanserin) for Parkinson's disease psychosis (PDP) and Daybue/Daybu (trofinetide) for Rett syndrome. So, we believe commercial execution remains a key stock driver. At the same time, despite recent strength, we also believe the company's pipeline, which targets several large/meaningful indications, remains underappreciated by investors. This is especially true as we approach a key clinical catalyst. Specifically,

Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Morgan Stanley

Tue, 25 Aug 2026 08:30:23 -0400

Morgan Stanley analyst Jeffrey Hung raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $27.00) while maintaining a Equalweight rating.

H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Tue, 25 Aug 2026 06:57:58 -0400

H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst commented: "Yesterday, the European Commission approved DAYBU (trofinetide) for the neurobehavioral symptoms of Rett syndrome in patients five years and older across the EU27 plus Iceland, Liechtenstein and Norway. In the ongoing debate on MFN pricing, we think Acadia’s EU launch and pricing negotiation can be an example for other SMID cap biotechs across our coverage. Towards that, we note a Yale team studied 79 drugs that would fall under the new U.S. pricing models and found that every orphan

Acadia Pharmaceuticals (ACAD) PT Raised to $40 at Citi

Tue, 25 Aug 2026 05:02:42 -0400

Citi analyst Yigel Nochomovitz raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $40.00 (from $39.00) while maintaining a Buy rating.

EU approves Acadia's trofinetide for Rett syndrome treatment

Mon, 24 Aug 2026 06:10:18 -0400

Acadia Pharmaceuticals (Nasdaq: ACAD) announced that the European Commission has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.

The company claims the drug is the first treatment approved for Rett syndrome in the European Union. The authorization covers all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.

The approval is based primarily on results from the Phase 3 LAVENDER study, which showed statistically significant improvements in core features of Rett syndrome as measured by the Rett Syndrome Behaviour Questionnaire and Clinical Global

EU approves Acadia's trofinetide for Rett syndrome treatment

Mon, 24 Aug 2026 06:10:18 -0400

The company claims the drug is the first treatment approved for Rett syndrome in the European Union. The authorization covers all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union